Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Influence of Hormone Therapy on Heart Attack Incidence in Men Undergoing Prostate Brachytherapy

This study has been completed.
Information provided by:
Prostate Cancer Foundation of Chicago Identifier:
First received: March 31, 2008
Last updated: NA
Last verified: March 2008
History: No changes posted

The purpose of this study is to review cause of death in patients undergoing prostate brachytherapy at a single institution. Furthermore, we are analyzing patients undergoing androgen deprivation therapy and whether or not this contributed to cardiovascular deaths, specifically myocardial infarction.

Condition Intervention
Prostate Cancer
Cardiovascular Death
Other: No intervention was required

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Influence of Androgen Suppression Therapy for Prostate Cancer on the Timing and Onset of Fatal Myocardial Infarctions in Men Undergoing Prostate Brachytherapy

Resource links provided by NLM:

Further study details as provided by Prostate Cancer Foundation of Chicago:

Groups/Cohorts Assigned Interventions
All deceased patients who underwent brachytherapy at Chicago Prostate Center between 10/14/1997 and 6/15/2007
Other: No intervention was required
Death records were reviewed, therefore, there was no intervention
Other Name: Death records were reviewed, therefore, there was no intervention


Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Prostate cancer patients treated with prostate brachytherapy at an ambulatory surgery center


Inclusion Criteria:

  • Deceased anytime after prostate brachytherapy treatment

Exclusion Criteria:

  • Patients whose cause of death was unable to be determined
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00651222

United States, Illinois
Chicago Prostate Center
Westmont, Illinois, United States, 60559
Sponsors and Collaborators
Prostate Cancer Foundation of Chicago
  More Information

No publications provided

Responsible Party: Brian J. Moran, MD, Prostate Cancer Foundation of Chicago Identifier: NCT00651222     History of Changes
Other Study ID Numbers: MI-PB
Study First Received: March 31, 2008
Last Updated: March 31, 2008
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms processed this record on February 27, 2015